Dicot

The European Society for Sexual Medicine (ESSM) is Europe's leading scientific organization in sexual medicine. Its annual conference gathers prominent researchers and clinicians from around the globe. This time, experts will convene at the historic University of Vienna, February 20–22, 2025.

The potency drug developer Dicot Pharma completed its phase 1 study earlier this year. Exploratory results from the study of the candidate LIB-01 revealed a clear efficacy signal, with one dose group demonstrating clinically relevant and statistically significant improvement in erectile function. Also notable was the duration of LIB-01’s effect – four weeks after dosing.

The company is now conducting its phase 2a study, with Professor François Giuliano as its medical expert. Professor Giuliano is a renowned urologist specializing in male sexual health, and the former president of ESSM.

“The results shown by Dicot Pharma are unique. The efficacy signal observed in the phase 1 study, with improved erectile function lasting four weeks, has never been reported for a drug targeting erectile dysfunction. LIB-01 has the potential to become a game changer in the landscape of the medical treatment for erectile dysfunction. Sharing this with the European medical community and serving as the medical expert for Dicot Pharma's Phase 2a study is very exciting,” says Professor Giuliano.